Cerus Corp (CERS) Misses Q1 EPS by 10c, Comments on Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Cerus Corp (CERS) Enters INTERCEPT Blood System Agreement w/ Karolinska University Hospital
February 27, 2015 8:40 AM ESTCerus Corp (NASDAQ: CERS) announced that the Karolinska University Hospital (KUH) in Stockholm, has signed a three-year agreement to purchase the INTERCEPT Blood System for platelets. In addition to the three-year base term, the agreement allows for automatic annual extensions for an additional two years. KUH is Swedens largest platelet supplier and one of the largest University Hospitals in Europe, producing over 10,000 platelet units, or 20% of Swedens platelet... More
Cerus (CERS) PT Lowered to $6.50 at Wedbush Post Q4; 'Outperform' Maintained
February 27, 2015 7:16 AM ESTWedbush analyst Zarak Khurshid trimmed its price target on Cerus (NASDAQ: CERS) to $6.50 (from $7.50) but maintained an Outperform rating following results.
Khurshid notes, "Adjusted EPS loss roughly in-line. CERS reported 4Q14 sales of $9.7 MM and adjusted EPS loss of ($0.16), missing our $10.4 MM... More
